Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
暂无分享,去创建一个
A. Lenaerts | Richard E. Lee | Jiuyu Liu | M. Scherman | Lei Yang | Rakesh | David F. Bruhn | A. Singh
[1] Matthew D. Zimmerman,et al. The association between sterilizing activity and drug distribution into tuberculosis lesions , 2015, Nature Medicine.
[2] A. Spanevello,et al. New anti-tuberculosis drugs and regimens: 2015 update , 2015, ERJ Open Research.
[3] M. Gurumurthy,et al. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis , 2014, PloS one.
[4] M. Voskuil,et al. Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas , 2014, Antimicrobial Agents and Chemotherapy.
[5] B. Meibohm,et al. Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux , 2014, Nature Medicine.
[6] V. Dartois,et al. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. , 2013, Bioorganic & medicinal chemistry letters.
[7] E. J. North,et al. Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. , 2013, Bioorganic & medicinal chemistry.
[8] D. Follmann,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.
[9] W. Denny,et al. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2012, Journal of medicinal chemistry.
[10] P. Niyomrattanakit,et al. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). , 2011, Journal of medicinal chemistry.
[11] W. Denny,et al. Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824) , 2010 .
[12] W. Denny,et al. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2010, Journal of medicinal chemistry.
[13] P. Niyomrattanakit,et al. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. , 2009, Journal of medicinal chemistry.
[14] W. Denny,et al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2009, Journal of medicinal chemistry.
[15] Dianqing Sun,et al. Synthesis, optimization and structure-activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. , 2009, European journal of medicinal chemistry.
[16] Pilho Kim,et al. PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.
[17] B. Meibohm,et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. , 2008, The Journal of antimicrobial chemotherapy.
[18] C. Lipinski,et al. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. , 2008, Bioorganic & medicinal chemistry letters.
[19] Robert C. Reynolds,et al. Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models , 2005, Antimicrobial Agents and Chemotherapy.
[20] D. Menzies,et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[21] Clifton E. Barry,et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.